CONNECT WITH US
HealthTech

HealthTech

Maven Clinic takes new DTC vertical in-network with 475+ commercial plans

Fierce Healthcare logo

Published on

Add as a preferred source on Google
Maven Clinic takes new DTC vertical in-network with 475+ commercial plans

Maven Clinic, a virtual provider for women’s and family health, is making its new DTC vertical in-network with over 475 commercial health plans.

The first program to be in-network, starting now, is hormone care. Starting on Jan. 1, 2027, its GLP-1 program will also be covered. The fee-for-service contracts represent about 80% of commercially insured lives, according to the company. It is able to tap into the vast network through direct contracts and a third-party partner that it can’t name on the record. Coverage and applicable copays will vary by plan.

“We’re really doing this because of access [gaps]…the in network coverage removes that barrier,” Alex Kubal, general manager of Maven's Consumer Division, told Fierce Healthcare.

Also in 2027, Maven plans to roll out in its DTC vertical several additional specialties, including OBGYN care, maternal-fetal medicine, nurse practitioners for general women’s health and nutrition. Employees can use their health plan to get care for PMOS, endometriosis, hormonal, sexual or metabolic health, regardless of whether or not their employer sponsors a Maven program. Cash pay will also remain available.

“We need to be able to maintain pathways for both,” Kubal said. “We want people to get access to high-quality clinical care, which we see as a gap in the market.”

Since the DTC vertical is relatively new, a notable portion of traffic has come from patients already familiar with the brand. About a third of Maven’s DTC subscribers have had a previous touchpoint with Maven, though that doesn’t necessarily mean they have it as a full benefit.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.